In total, 150 protein extracts from 94 different basidiomycete and ascomycete wild mushroom species were tested for antibacterial activity against the quarantine plant-pathogen bacterium Ralstonia solanacearum. In in vitro microtiter plate assays, 15 extracts with moderate to high antibacterial activities were identified: 11 completely inhibited bacterial growth and 4 showed partial inhibition. Of these 15 extracts, 5 were further tested and 3 extracts slowed disease progression and reduced disease severity in artificially inoculated tomato and potato plants. However, the in vitro activities of the extracts did not always correlate with their in vivo activities, which emphasizes the importance of performing early screening tests also in vivo. Testing of selected extracts against 12 R. solanacearum strains identified 6 with potential for broader applicability. Further analysis of extracts from Amanita phalloides and Clitocybe geotropa showed that the active substances are proteins with an approximate size of 180 kDa. To our knowledge, this is the first in vitro and in vivo study that demonstrates that mushroom protein extracts can be promising for treatment of bacterial wilt caused by R. solanacearum.
No takes yet. Share an insight, caveat, or question.
Erjavec et al. (2015) studied this question.
Synapse has enriched 4 closely related papers on similar clinical questions. Consider them for comparative context: